Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients
Information source: Boehringer Ingelheim Pharmaceuticals
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension; Cardiovascular Diseases
Phase: N/A
Status: Not yet recruiting
Sponsored by: Boehringer Ingelheim Pharmaceuticals Official(s) and/or principal investigator(s):
Boehringer Ingelheim, Study Chair, Affiliation: Boehringer Ingelheim Pharmaceuticals
Overall contact:
Boehringer Ingelheim Study Coordinator, Phone: 1-800-243-0127, Email: clintriage.rdg@boehringer-ingelheim.com
Summary
The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on
blood pressure and its ability to reduce different indicated cardiovascular risks. Further
on, the study will evaluate the current antihypertensive treatment pattern in the daily
practice among the patient population at increased cardiovascular risk.
Clinical Details
Official title: Evaluation of the Effect of Telmisartan on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients
Study design: Other, Prospective
Primary outcome: The primary endpoint is treatment efficacy on reducing blood pressure and its ability to reduce cardiovascular risk.
Secondary outcome: Evaluation of antihypertensive treatment pattern
Determine number of patients (percentage) that achieve target blood pressure values according to the ESH/ESC values
Detailed description:
Study Design:
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- diagnosis of essential arterial hypertension (BP>140/90 mm HG or BP>130/80 mm Hg for
diabetic patients)
- at least an additional cardiovascular risk factor
Exclusion Criteria:
- hypersensitivity to the active substance or to any of the excipients in any ACE
inhibitor or angiotensin receptor blocker (ARB) available on the local market
- pregnancy and lactation
- diseases involving biliary obstruction
- severe liver impairment
Locations and Contacts
Boehringer Ingelheim Study Coordinator, Phone: 1-800-243-0127, Email: clintriage.rdg@boehringer-ingelheim.com Additional Information
Starting date: November 2009
Last updated: October 13, 2009
|
